This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Q2 FY27 consolidated revenue up 38%, profit after tax up 44% from Q2 FY26; USD 1m Hester Africa loan
HESTERBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Q2 FY27 consolidated revenue was INR 979.12 million, up 38% from INR 709.69 million in Q2 FY26; profit after tax was INR 206.31 million, up 44% from INR 143.31 million. Consolidated EBITDA margin rose to 37% from 33%. Q2 included an INR 4.19 million exceptional gain. H1 FY27 consolidated profit included an INR 857.68 million Gates Foundation loan gain. Board approved a USD 1 million unsecured loan to Hester Africa at 9 percent for working capital.
Strong Q2 growth supports sentiment, but H1 profit is inflated by a one-time gain; the USD 1 million subsidiary loan adds modest funding exposure.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹97.91 Cr | ₹70.97 Cr | +38.0% |
| Operating profit | ₹22.60 Cr | ₹5.16 Cr | +338.2% |
| Profit after tax | ₹20.63 Cr | ₹14.33 Cr | +44.0% |
| EBITDA margin | 33.8% | 16.5% | +17.3 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.